SCHOTT Pharma Reports Preliminary 2025 Financial Results

SCHOTT Pharma has released its preliminary financial results for fiscal year 2025, forecasting revenues of EUR 986.2 million, reflecting a growth of 5.8% at constant currencies. The company's EBITDA is expected to reach EUR 280.3 million, translating to an EBITDA margin of 28.4%, up from 26.9% in the previous year.

Looking ahead to fiscal year 2026, SCHOTT Pharma anticipates a more modest revenue growth of 2-5% and an EBITDA margin of around 27%. The company acknowledges potential challenges, particularly in the Drug Delivery Systems segment, due to changing demand from a major customer.

For the mid-term, from 2027 to 2029, SCHOTT Pharma has revised its outlook to a revenue CAGR of 6-8%, with expectations of the EBITDA margin climbing towards 30%. These projections are underpinned by the company's strong innovation pipeline and strategic customer partnerships.